What’s next for Alzheimer’s research after the failure of yet another once-promising drug
The failure last week of Biogen Inc. and Eisai Co.’s once-promising Alzheimer’s disease drug was the latest in a spate of disappointments for medicines designed to target Beta amyloid, a sticky substance long known to accumulate in the brains of people with the disease.
The repeated failure of such drugs are giving greater currency to efforts by academics and smaller biotech companies to better understand the biology of Alzheimer’s and explore the use of drugs with alternative mechanisms of action. Some of the more promising...
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
House Dems push resolution to condemn global anti-Israel boycotts ahead of AIPACA pair of Jewish Democrats are pushing a new measure to condemn an international boycott campaign aimed at Israel, a chance for much of the party to unify around support for the key U.S. ally after weeks of turmoil on the issue
Read more »
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex...
Read more »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab.
Read more »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Read more »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Read more »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Read more »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Read more »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
Read more »
Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trialsEisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orde...
Read more »
Eisai starts phase 3 trials for second Alzheimer's drug after first's failureEisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer&0...
Read more »